King International Investment Limited (HKG:0928)
0.1000
-0.0030 (-2.91%)
At close: Jan 30, 2026
HKG:0928 Revenue
King International Investment had revenue of 73.92M HKD in the half year ending September 30, 2025, a decrease of -11.40%. This brings the company's revenue in the last twelve months to 77.50M, down -58.65% year-over-year. In the fiscal year ending March 31, 2025, King International Investment had annual revenue of 40.77M, down -82.56%.
Revenue (ttm)
77.50M
Revenue Growth
-58.65%
P/S Ratio
2.39
Revenue / Employee
5.96M
Employees
13
Market Cap
185.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 40.77M | -192.92M | -82.56% |
| Mar 31, 2024 | 233.68M | 9.83M | 4.39% |
| Mar 31, 2023 | 223.85M | 130.98M | 141.03% |
| Mar 31, 2022 | 92.87M | -9.17M | -8.98% |
| Mar 31, 2021 | 102.04M | 38.24M | 59.93% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi XDC Cayman | 5.58B |
| Adicon Holdings | 2.98B |
| Kindstar Globalgene Technology | 998.42M |
| Yunkang Group | 706.95M |
| Biosino Bio-Technology and Science Incorporation | 246.61M |
| Mega Genomics | 171.61M |
| Guanze Medical Information Industry (Holding) | 161.70M |
| China Biotech Services Holdings | 76.93M |